# RGS1

## Overview
RGS1 (Regulator of G protein signaling 1) is a gene that encodes a regulatory protein involved in the modulation of G protein-coupled receptor (GPCR) signaling pathways. The protein, also named RGS1, functions as a GTPase-activating protein (GAP) for Gα subunits, thereby accelerating the hydrolysis of GTP to GDP and terminating GPCR signaling. This regulatory activity is crucial for maintaining the specificity and balance of signaling pathways, particularly within immune cells, where RGS1 is highly expressed. The protein plays a significant role in immune cell migration and response by modulating chemokine receptor signaling, impacting the positioning and function of cells such as lymphocytes and monocytes. RGS1's interactions with various proteins and its involvement in multiple signaling pathways underscore its importance in both normal immune function and disease states, including cancer and autoimmune disorders (Kehrl2016The; Lee2016Regulator; Ross2000GTPaseActivating).

## Function
RGS1 (Regulator of G protein signaling 1) is a protein that plays a critical role in modulating G protein-coupled receptor (GPCR) signaling pathways. It functions as a GTPase-activating protein (GAP) for Gα subunits, accelerating the hydrolysis of GTP to GDP, which effectively terminates the signaling activity of GPCRs (Ross2000GTPaseActivating). This regulatory mechanism is crucial for maintaining the balance and specificity of signaling pathways, particularly in immune cells (Kehrl2016The).

RGS1 is highly expressed in various immune cells, including lymphocytes, dendritic cells, and monocytes, where it influences cell migration and immune responses by modulating chemokine receptor signaling (Kehrl2016The; Lee2016Regulator). In B lymphocytes, RGS1 impairs Gαi signaling responses, affecting chemokine responsiveness and desensitization, which is essential for proper immune cell positioning and function (Lee2016Regulator).

The protein is also involved in the regulation of immune cell signaling by acting as a GAP for Gαi proteins, which are critical for the signaling pathways that govern immune cell localization and migration (Kehrl2016The). RGS1's activity is modulated by various stimuli, including hypoxia and interferons, which can upregulate its expression (Kehrl2016The).

## Clinical Significance
RGS1 (regulator of G protein signaling 1) has been implicated in several diseases due to alterations in its expression levels and interactions. In multiple sclerosis (MS), RGS1 is identified as a susceptibility locus, with higher expression levels observed in patients. Its expression is induced by interferon-γ therapy, and it plays a role in immune cell migration, particularly affecting microglia involved in MS progression (Lee2016Regulator). 

In the context of cancer, RGS1 expression is associated with poor prognosis in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). In DLBCL, RGS1 is linked to poor outcomes, with its expression correlating with a pro-tumoral immune microenvironment characterized by M2-like macrophage polarization (Carreras2023Mutational). In MM, high RGS1 expression is associated with advanced disease stages and inferior overall survival, suggesting its role as an independent prognostic factor. It is involved in signaling pathways crucial for MM pathogenesis, such as IGFR1, PIK3/AKT, and MAPK (Hafez2023Prognostic).

RGS1 is also implicated in autoimmune diseases like Crohn's disease and ulcerative colitis, where genetic evidence shows a correlation between RGS1 polymorphisms and disease diagnosis (Lee2016Regulator).

## Interactions
RGS1 interacts with various proteins, playing a significant role in modulating G protein-coupled receptor (GPCR) signaling pathways. It is known to regulate Gα subunits by accelerating their GTPase activity, which leads to the termination of signaling. RGS1 has a broad regulatory capacity, interacting with all Gi/o- and Gq-type proteins, making it one of the more promiscuous RGS proteins in terms of substrate regulation (Masuho2020A).

RGS1 also interacts with scaffolding proteins such as spinophilin, which binds to RGS1 and other RGS proteins. Spinophilin is involved in forming signaling complexes by interacting with the third intracellular loop of several GPCRs, suggesting a role in modulating receptor signaling (AbramowNewerly2006RGS).

In the context of cervical cancer, RGS1 is associated with several genes, including RGS2, GNAO1, and GNAI2, through a protein-protein interaction network. These interactions are linked to the adenylate cyclase-modulating GPCR signaling pathway and protein folding, indicating RGS1's involvement in immune response modulation and cancer progression (Zhang2022RGS1).


## References


[1. (Kehrl2016The) John H. Kehrl. The impact of rgs and other g-protein regulatory proteins on gαi-mediated signaling in immunity. Biochemical Pharmacology, 114:40–52, August 2016. URL: http://dx.doi.org/10.1016/j.bcp.2016.04.005, doi:10.1016/j.bcp.2016.04.005. This article has 40 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bcp.2016.04.005)

[2. (Lee2016Regulator) Jae-Kyung Lee and Josephine Bou Dagher. Regulator of g-protein signaling (rgs)1 and rgs10 proteins as potential drug targets for neuroinflammatory and neurodegenerative diseases. The AAPS Journal, 18(3):545–549, February 2016. URL: http://dx.doi.org/10.1208/s12248-016-9883-4, doi:10.1208/s12248-016-9883-4. This article has 24 citations.](https://doi.org/10.1208/s12248-016-9883-4)

[3. (AbramowNewerly2006RGS) Maria Abramow-Newerly, Anju A. Roy, Caroline Nunn, and Peter Chidiac. Rgs proteins have a signalling complex: interactions between rgs proteins and gpcrs, effectors, and auxiliary proteins. Cellular Signalling, 18(5):579–591, May 2006. URL: http://dx.doi.org/10.1016/J.CELLSIG.2005.08.010, doi:10.1016/j.cellsig.2005.08.010. This article has 300 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/J.CELLSIG.2005.08.010)

[4. (Ross2000GTPaseActivating) Elliott M. Ross and Thomas M. Wilkie. Gtpase-activating proteins for heterotrimeric g proteins: regulators of g protein signaling (rgs) and rgs-like proteins. Annual Review of Biochemistry, 69(1):795–827, June 2000. URL: http://dx.doi.org/10.1146/annurev.biochem.69.1.795, doi:10.1146/annurev.biochem.69.1.795. This article has 940 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1146/annurev.biochem.69.1.795)

[5. (Masuho2020A) Ikuo Masuho, Santhanam Balaji, Brian S. Muntean, Nickolas K. Skamangas, Sreenivas Chavali, John J.G. Tesmer, M. Madan Babu, and Kirill A. Martemyanov. A global map of g protein signaling regulation by rgs proteins. Cell, 183(2):503-521.e19, October 2020. URL: http://dx.doi.org/10.1016/j.cell.2020.08.052, doi:10.1016/j.cell.2020.08.052. This article has 85 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cell.2020.08.052)

[6. (Hafez2023Prognostic) Nora Hafez, Lobna Refaat, Omnia K. ElGebaly, Hossam M. Elhariry, Mohammed Ghareeb, and Lamiaa A. Fathalla. Prognostic value of rgs1 and mtor immunohistochemical expression in egyptian multiple myeloma patients; a single center study. PLOS ONE, 18(7):e0288357, July 2023. URL: http://dx.doi.org/10.1371/journal.pone.0288357, doi:10.1371/journal.pone.0288357. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0288357)

[7. (Zhang2022RGS1) Siyang Zhang, Han Wang, Jiao Liu, Tao Tao, Zhi Zeng, and Min Wang. Rgs1 and related genes as potential targets for immunotherapy in cervical cancer: computational biology and experimental validation. Journal of Translational Medicine, July 2022. URL: http://dx.doi.org/10.1186/s12967-022-03526-0, doi:10.1186/s12967-022-03526-0. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12967-022-03526-0)

[8. (Carreras2023Mutational) Joaquim Carreras, Yara Yukie Kikuti, Masashi Miyaoka, Shinichiro Hiraiwa, Sakura Tomita, Haruka Ikoma, Yusuke Kondo, Atsushi Ito, Shunsuke Nagase, Hisanobu Miura, Giovanna Roncador, Lluis Colomo, Rifat Hamoudi, Elias Campo, and Naoya Nakamura. Mutational profile and pathological features of a case of interleukin-10 and rgs1-positive spindle cell variant diffuse large b-cell lymphoma. Hematology Reports, 15(1):188–200, March 2023. URL: http://dx.doi.org/10.3390/hematolrep15010020, doi:10.3390/hematolrep15010020. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/hematolrep15010020)